Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Mckinsey To Pay 0 Million In Purdue Pharma Settlement

McKinsey & Company agrees to pay 0 million in settlement for its role in Purdue Pharma's opioid crisis, impacting addiction and overdose prevention efforts.

Top News

McKinsey & Company agrees to pay $650 million to settle federal probe over opioids work

McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia

The Independent UK

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Vifor Pharma to pay £23m to NHS after competition probe into misleading claims

The competition watchdog was investigating whether the drugs firm had been spreading misleading information on a rival’s treatment.

The Independent UK

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

Benzinga

Worker Reveals Shocking Reason Why Women Should Check The Toilet Paper When in Walmart Washrooms

Walmart employee warns women about IV drug users cleaning needles in toilet paper rolls, sparking public health concerns and fear.

International Business Times UK

Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma

During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

4 Analysts Assess Amylyx Pharma: What You Need To Know

During the last three months, 4 analysts shared their evaluations of Amylyx Pharma (NASDAQ:AMLX), revealing diverse outlooks from bullish to bearish.

Benzinga

Warren Buffett's Portfolio Stock Kroger Pauses Buybacks For Albertsons Merger, Narrows FY24 Outlook

Kroger pauses share buybacks for the Albertsons merger, misses Q3 sales estimates, and narrows its FY24 EPS guidance.

Benzinga

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

Shares of Verint Systems Inc. (NASDAQ:VRNT) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial results.

Benzinga

Danish Medical Marijuana Producer Stenocare To Launch Patented 10mg THC And 10mg CBD Oil In Norway

A publicly traded Danish medical marijuana operator Stenocare announced Monday the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next…

Benzinga

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Benzinga

Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump

Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.

Benzinga

Hemi Pharma for Sale: “Hemi Pharma for Sale: Advanced Supplements for Peak Performance”

The pursuit of peak performance-whether in athletics, academics, or day-to-day life-has led to an increased demand for supplements that deliver more than just marginal gains. This is where Hemi Pharma for Sale steps in, offering a game-changing ...

USA Today Sports Media Group

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

5 Analysts Assess PROCEPT BioRobotics: What You Need To Know

In the last three months, 5 analysts have published ratings on PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse range of perspectives from bullish to bearish.

Benzinga

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

StockNews.com

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

Dynamite News

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Benzinga

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

AMD stock faces bearish wave, below key moving averages with neutral RSI. Short-term rebound possible, but overall technicals and market share gains uncertain.

Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Milestone Scientific Secures Federal Supply Schedule Approval On Contract For CompuFlo Epidural System

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced its approval on contract for the Federal Supply Schedule

Benzinga

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

1 … 27 28 29 30

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.